CTOs on the Move

HTG Molecular Diagnostics

www.htgmolecular.com

 
Headquartered in Tucson, Arizona, HTG is focused on advancing precision medicine. The company`s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

HTG Molecular Diagnostics raised $22.5M on 10/03/2019

Similar Companies

Marengo Therapeutics

Marengo Therapeutics is pioneering an entirely new way to activate the body`s own immune system to mount a rapid, effective, and durable response against cancer. Our unique therapeutic platform selectively boosts T cells, turbocharging potent anti-tumor activity and promoting long-term immunity to keep cancer at bay.

ATS Scientific

ATS Scientific Inc. is a Burlington, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IDM Pharma

IDM Pharma is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Deepcell

Our mission is to enable novel biological insights at the single-cell level for improved diagnosis and treatment of disease.

Be Biopharma

Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body`s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., Be Biopharma is re-imagining medicine based on the power of B cell therapy. Be Bio was founded in October 2020 by Longwood Fund with a $52 million Series A investment led by Atlas Ventures and RA Capital, joined by Alta Partners and Takeda Ventures.